

# Highly Synergistic Drug Combination Prevents Vaginal HIV Infection in Humanized Mice

Marc M. Baum<sup>1\*</sup>, Christina M. Ramirez<sup>2</sup>, John A. Moss<sup>1</sup>, Manjula Gunawardana<sup>1</sup>, Michael Bobardt<sup>3</sup>, Philippe A. Gallay<sup>3\*</sup>

<sup>1</sup>Department of Chemistry, Oak Crest Institute of Science, 128-132 W. Chestnut Ave., Monrovia, CA, USA

<sup>2</sup>University of California, Los Angeles (UCLA) Fielding School of Public Health, 650 Charles E. Young Dr. South, 16-035 Center for Health Sciences, Los Angeles, CA, USA

<sup>3</sup>Department of Immunology & Microbiology, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA, USA

\*email: [m.baum@oak-crest.org](mailto:m.baum@oak-crest.org); [gallay@scripps.edu](mailto:gallay@scripps.edu)

## **Supplementary Information**

The Supplementary Information includes the following data:


**Figure S1:** VRC01-*N* SDS-PAGE and Western blot images.

**Appendix A:** BLT mouse efficacy data from HIV vaginal challenge studies following vaginal administration of VRC01-*N*.

**Appendix B:** BLT mouse efficacy data from HIV vaginal challenge studies following vaginal administration of VRC01-*N*, TDF, FTC (broad dosing range).

**Appendix C:** BLT mouse efficacy data from HIV vaginal challenge studies following vaginal administration of VRC01-*N*, TDF, FTC (narrow dosing range).

**Appendix D:** Median-effect data used in the analysis.



**Figure S1.** PAGE and Western blot analysis of VRC01. **A:** Coomassie-stained SDS-PAGE gel showing VRC01-*N*. **i:** NIH AIDS Reagent Program VRC01 reference material, 0.60  $\mu\text{g well}^{-1}$ ; **ii:** VRC01-*N* produced in *Nicotiana* spp. (2014), this study, 0.33  $\mu\text{g well}^{-1}$ ; **iii:** VRC01-*N* produced in *Nicotiana* spp. (2018), 0.31  $\mu\text{g well}^{-1}$ . **B:** Western blot of VRC01-*N* (this study) over a 0.01-5  $\mu\text{g well}^{-1}$  range. **i:** 0.01  $\mu\text{g}$ ; **ii:** 0.05  $\mu\text{g}$ ; **iii:** 0.075  $\mu\text{g}$ ; **iv:** 0.1  $\mu\text{g}$ ; **v:** 0.25  $\mu\text{g}$ ; **vi:** 0.5  $\mu\text{g}$ ; **vii:** 0.75  $\mu\text{g}$ ; **viii:** 1.0  $\mu\text{g}$ ; **ix:** 5.0  $\mu\text{g}$ .

**Appendix A: BLT mouse efficacy data from HIV vaginal challenge studies following vaginal administration of VRC01-N.**

Mice	Human CD45+ cells (% +/- S.D.)	Human T cells (% +/- S.D.)	HIV-1 positive mice	Week 1	Week 2	Week 3	Week 6	Week 12	VRC01	% of Protection
1	66.2 +/- 0.3	79.2 +/- 1	N	0	0	0	0	0	1 mg/mL	100%
2	69.9 +/- 0.5	81.2 +/- 0.9	N	0	0	0	0	0		
3	70.3 +/- 0.5	77.3 +/- 1.1	N	0	0	0	0	0		
4	69.2 +/- 0.4	77.9 +/- 0.7	N	0	0	0	0	0		
5	66.9 +/- 0.5	78.6 +/- 1.2	N	0	0	0	0	0		
6	67.5 +/- 0.5	77.6 +/- 0.8	N	0	0	0	0	0		
7	70.1 +/- 0.4	80.1 +/- 0.7	N	0	0	0	0	0		
8	66.9 +/- 0.5	81.5 +/- 1.1	N	0	0	0	0	0		
Mice	Human CD45+ cells (% +/- S.D.)	Human T cells (% +/- S.D.)	HIV-1 positive mice	Week 1	Week 2	Week 3	Week 6	Week 12	VRC01	% of Protection
1	69.5 +/- 0.8	76.9 +/- 1.2	N	0	0	0	0	0	0.5 mg/mL	100%
2	67.9 +/- 0.7	78.2 +/- 0.8	N	0	0	0	0	0		
3	66.4 +/- 0.8	80.1 +/- 1.1	N	0	0	0	0	0		
4	70.1 +/- 0.5	78.6 +/- 1.3	N	0	0	0	0	0		
5	69.5 +/- 0.6	79.7 +/- 1.4	N	0	0	0	0	0		
6	69.3 +/- 0.7	79.4 +/- 1.3	N	0	0	0	0	0		
7	65.6 +/- 0.5	80.5 +/- 1.5	N	0	0	0	0	0		
8	69.1 +/- 0.7	78.7 +/- 1	N	0	0	0	0	0		
Mice	Human CD45+ cells (% +/- S.D.)	Human T cells (% +/- S.D.)	HIV-1 positive mice	Week 1	Week 2	Week 3	Week 6	Week 12	VRC01	% of Protection
1	68.8 +/- 1.1	76.7 +/- 1.4	N	0	0	0	0	0	0.25 mg/mL	50%
2	66.8 +/- 0.9	78.4 +/- 1.2	N	0	0	0	0	0		
3	70 +/- 1	75.6 +/- 1.5	Y	0.9 +/- 0.2	1.1 +/- 0.2	1.2 +/- 0.3	1.9 +/- 0.4	1.8 +/- 0.3		
4	69.2 +/- 0.9	80.2 +/- 1.3	N	0	0	0	0	0		
5	67.5 +/- 0.7	79.1 +/- 1.1	Y	0.7 +/- 0.2	1 +/- 0.3	1.3 +/- 0.4	2.1 +/- 0.8	1.9 +/- 0.7		
6	64.9 +/- 0.9	77.8 +/- 1.3	Y	0.9 +/- 0.3	1.2 +/- 0.3	1.4 +/- 0.6	1.8 +/- 0.5	2 +/- 0.6		
7	70.1 +/- 1.2	79.3 +/- 1.4	Y	0.8 +/- 0.4	1.1 +/- 0.2	1.5 +/- 0.4	2 +/- 0.6	1.8 +/- 0.2		
8	68.7 +/- 0.9	77.2 +/- 1.1	N	0	0	0	0	0		
Mice	Human CD45+ cells (% +/- S.D.)	Human T cells (% +/- S.D.)	HIV-1 positive mice	Week 1	Week 2	Week 3	Week 6	Week 12	VRC01	% of Protection
1	69.1 +/- 1.1	77.3 +/- 1.1	Y	0.8 +/- 0.2	1.2 +/- 0.3	1.4 +/- 0.3	1.7 +/- 0.3	1.9 +/- 0.4	0.125 mg/mL	13%
2	66.8 +/- 0.7	76.8 +/- 1.3	Y	1 +/- 0.3	1.3 +/- 0.4	1.5 +/- 0.4	1.9 +/- 0.4	1.8 +/- 0.2		
3	70.1 +/- 0.6	78.2 +/- 1.5	Y	0.7 +/- 0.2	0.9 +/- 0.2	1.2 +/- 0.2	1.7 +/- 0.2	1.9 +/- 0.4		
4	67.4 +/- 0.8	80.1 +/- 1.2	Y	0.9 +/- 0.2	1.1 +/- 0.3	1.3 +/- 0.4	2.1 +/- 0.4	1.9 +/- 0.3		
5	65.7 +/- 0.6	76.4 +/- 0.7	Y	0.8 +/- 0.1	1 +/- 0.2	1.2 +/- 0.3	1.9 +/- 0.3	1.9 +/- 0.5		
6	68.3 +/- 0.3	79.3 +/- 1.3	N	0	0	0	0	0		
7	67.6 +/- 0.4	78.4 +/- 0.7	Y	0.9 +/- 0.3	1.2 +/- 0.2	1.4 +/- 0.1	2.2 +/- 0.4	2 +/- 0.3		
8	70.1 +/- 0.5	77.1 +/- 1.4	Y	0.8 +/- 0.2	1 +/- 0.3	1.2 +/- 0.3	1.8 +/- 0.3	1.9 +/- 0.4		
Mice	Human CD45+ cells (% +/- S.D.)	Human T cells (% +/- S.D.)	HIV-1 positive mice	Week 1	Week 2	Week 3	Week 6	Week 12	VRC01	% of Protection
1	68.2 +/- 1.0	76.9 +/- 1.3	Y	0.6 +/- 0.2	0.8 +/- 0.2	1.2 +/- 0.3	1.6 +/- 0.3	1.9 +/- 0.4	0.0625 mg/mL	0%
2	66.9 +/- 0.7	78.1 +/- 1.1	Y	0.9 +/- 0.3	1.1 +/- 0.1	1.4 +/- 0.4	1.8 +/- 0.4	2.0 +/- 0.3		
3	70.3 +/- 0.4	75.4 +/- 1.2	Y	1.0 +/- 0.2	1.2 +/- 0.3	1.5 +/- 0.2	1.9 +/- 0.3	2.2 +/- 0.4		
4	67.7 +/- 1.2	78.2 +/- 1.1	Y	0.8 +/- 0.2	1.0 +/- 0.2	1.3 +/- 0.2	1.7 +/- 0.2	1.9 +/- 0.3		
5	65.7 +/- 0.6	81.2 +/- 0.9	Y	0.9 +/- 0.2	1.2 +/- 0.2	1.4 +/- 0.4	2.1 +/- 0.4	1.8 +/- 0.4		
6	67.1 +/- 0.5	77.6 +/- 1.2	Y	0.7 +/- 0.1	0.9 +/- 0.2	1.2 +/- 0.3	1.7 +/- 0.3	1.8 +/- 0.3		
7	68.7 +/- 0.4	78.1 +/- 0.7	Y	1.1 +/- 0.3	1.3 +/- 0.3	1.5 +/- 0.4	1.9 +/- 0.2	2.1 +/- 0.4		
8	70.5 +/- 0.6	76.1 +/- 1.1	Y	0.8 +/- 0.1	1.1 +/- 0.2	1.3 +/- 0.3	2.0 +/- 0.4	1.9 +/- 0.3		

Plasma viral RNA (10<sup>5</sup> copies/mL)

**NOTE: VRC01-N active makes up 50% of the mass indicated above; the remainder consists of excipients**

**Appendix B:** BLT mouse efficacy data from HIV vaginal challenge studies following vaginal administration of VRC01-N, TDF, FTC (broad dosing range).

Mice	Human CD45+ cells (% +/- S.D.)	Human T cells (% +/- S.D.)	HIV-1 positive mice	Week 1	Week 2	Week 3	Week 6	Week 12	TDF/FTC/VRC01	% of Protection
1	70.2 +/- 0.3	75.5 +/- 1.0	N	0	0	0	0	0	1 µM TDF + 0.0625 µM FTC + 0.0625 mg/mL VRC01	20%
2	68.5 +/- 0.4	78.4 +/- 0.8	Y	0.8 +/- 0.1	1.2 +/- 0.4	1.5 +/- 0.3	1.9 +/- 0.3	1.9 +/- 0.2		
3	69.1 +/- 0.3	75.9 +/- 0.6	Y	0.7 +/- 0.2	1.1 +/- 0.2	1.4 +/- 0.2	2.0 +/- 0.2	2.1 +/- 0.3		
4	68.4 +/- 0.5	75.6 +/- 0.9	Y	0.5 +/- 0.1	0.9 +/- 0.1	1.6 +/- 0.3	2.2 +/- 0.4	2.1 +/- 0.1		
5	71.2 +/- 0.6	77.5 +/- 1.2	Y	0.6 +/- 0.2	0.9 +/- 0.2	1.4 +/- 0.2	2.1 +/- 0.5	1.9 +/- 0.4		
6	67.9 +/- 0.5	78.9 +/- 0.9	Y	0.9 +/- 0.2	1.2 +/- 0.2	1.3 +/- 0.4	1.9 +/- 0.2	2.0 +/- 0.2		
7	70.2 +/- 0.6	75.7 +/- 0.7	Y	0.7 +/- 0.1	1.1 +/- 0.1	1.6 +/- 0.3	2.1 +/- 0.3	1.9 +/- 0.3		
8	67.8 +/- 0.3	77.3 +/- 1.1	Y	0.6 +/- 0.2	0.9 +/- 0.2	1.4 +/- 0.1	1.9 +/- 0.2	2.0 +/- 0.3		
9	69.3 +/- 0.6	76.8 +/- 0.7	N	0	0	0	0	0		
10	65.8 +/- 0.3	78.5 +/- 0.9	Y	0.8 +/- 0.2	1.3 +/- 0.2	1.6 +/- 0.2	2.2 +/- 0.3	2.1 +/- 0.2		
Mice	Human CD45+ cells (% +/- S.D.)	Human T cells (% +/- S.D.)	HIV-1 positive mice	Week 1	Week 2	Week 3	Week 6	Week 12	2 µM TDF + 0.125 µM FTC + 0.125 mg/mL VRC01	100%
1	71.2 +/- 0.4	76.6 +/- 1.2	N	0	0	0	0	0		
2	69.5 +/- 0.7	74.9 +/- 0.8	N	0	0	0	0	0		
3	67.9 +/- 0.5	78.2 +/- 1.1	N	0	0	0	0	0		
4	70.1 +/- 0.7	78.8 +/- 0.7	N	0	0	0	0	0		
5	68.5 +/- 0.5	76.4 +/- 1.1	N	0	0	0	0	0		
6	66.9 +/- 0.7	77.4 +/- 1.2	N	0	0	0	0	0		
7	69.9 +/- 0.4	77.3 +/- 1.1	N	0	0	0	0	0		
8	68.5 +/- 0.6	75.8 +/- 0.6	N	0	0	0	0	0		
9	69.8 +/- 0.6	81.2 +/- 1.2	N	0	0	0	0	0		
10	68.4 +/- 0.5	78.3 +/- 0.9	N	0	0	0	0	0		
Mice	Human CD45+ cells (% +/- S.D.)	Human T cells (% +/- S.D.)	HIV-1 positive mice	Week 1	Week 2	Week 3	Week 6	Week 12	4 µM TDF + 0.25 µM FTC + 0.25 mg/mL VRC01	100%
1	69.3 +/- 0.6	77.5 +/- 1.2	N	0	0	0	0	0		
2	67.6 +/- 0.9	78.5 +/- 1.2	N	0	0	0	0	0		
3	70.1 +/- 0.5	74.5 +/- 0.8	N	0	0	0	0	0		
4	69.1 +/- 0.8	73.8 +/- 0.6	N	0	0	0	0	0		
5	65.4 +/- 1.1	77.2 +/- 0.9	N	0	0	0	0	0		
6	68.6 +/- 0.5	81.3 +/- 1.3	N	0	0	0	0	0		
7	65.6 +/- 0.8	79.4 +/- 0.8	N	0	0	0	0	0		
8	68.5 +/- 0.7	77.2 +/- 1.1	N	0	0	0	0	0		
9	71.2 +/- 0.6	75.6 +/- 1.2	N	0	0	0	0	0		
10	66.5 +/- 0.7	77.4 +/- 1.0	N	0	0	0	0	0		
Mice	Human CD45+ cells (% +/- S.D.)	Human T cells (% +/- S.D.)	HIV-1 positive mice	Week 1	Week 2	Week 3	Week 6	Week 12	8 µM TDF + 0.5 µM FTC + 0.5 mg/mL VRC01	100%
1	69.3 +/- 0.9	76.5 +/- 1.1	N	0	0	0	0	0		
2	65.8 +/- 0.6	74.9 +/- 1.2	N	0	0	0	0	0		
3	70.1 +/- 1.1	75.5 +/- 0.9	N	0	0	0	0	0		
4	66.8 +/- 0.8	77.6 +/- 1.1	N	0	0	0	0	0		
5	66.4 +/- 0.5	79.2 +/- 0.9	N	0	0	0	0	0		
6	68.3 +/- 0.9	81.0 +/- 1.3	N	0	0	0	0	0		
7	66.5 +/- 0.6	76.5 +/- 0.7	N	0	0	0	0	0		
8	71.2 +/- 0.7	79.2 +/- 1.1	N	0	0	0	0	0		
9	69.1 +/- 1.2	75.6 +/- 1.3	N	0	0	0	0	0		
10	66.4 +/- 0.9	77.5 +/- 1.2	N	0	0	0	0	0		
Mice	Human CD45+ cells (% +/- S.D.)	Human T cells (% +/- S.D.)	HIV-1 positive mice	Week 1	Week 2	Week 3	Week 6	Week 12	16 µM TDF + 1 µM FTC + 1 mg/mL VRC01	100%
1	69.2 +/- 1.0	76.1 +/- 1.1	N	0	0	0	0	0		
2	66.5 +/- 0.8	74.1 +/- 1.2	N	0	0	0	0	0		
3	68.4 +/- 0.6	75.4 +/- 1.1	N	0	0	0	0	0		
4	67.3 +/- 0.8	78.5 +/- 1.3	N	0	0	0	0	0		
5	67.4 +/- 0.9	74.7 +/- 0.9	N	0	0	0	0	0		
6	69.4 +/- 0.5	79.3 +/- 1.2	N	0	0	0	0	0		
7	66.4 +/- 0.8	75.4 +/- 0.8	N	0	0	0	0	0		
8	65.6 +/- 0.6	75.4 +/- 1.1	N	0	0	0	0	0		
9	69.4 +/- 0.9	76.3 +/- 1.3	N	0	0	0	0	0		
10	66.5 +/- 0.7	75.9 +/- 1.2	N	0	0	0	0	0		

Plasma viral RNA (10<sup>5</sup> copies/mL)

**NOTE:** VRC01-N active makes up 50% of the mass indicated above; the remainder consists of excipients

**Appendix C: BLT mouse efficacy data from HIV vaginal challenge studies following vaginal administration of VRC01-N, TDF, FTC (narrow dosing range).**

Mice	Human CD45+ cells (% +/- S.D.)	Human T cells (% +/- S.D.)	HIV-1 positive mice	Week 1	Week 2	Week 3	Week 6	Week 12	% of Protection
1	68.4 +/- 0.6	73.8 +/- 2.4	N	0	0	0	0	0	2 µM TDF + 0.125 µM FTC + 0.125 mg/mL VRC01
2	69.9 +/- 0.4	71.1 +/- 1.7	N	0	0	0	0	0	
3	70.1 +/- 0.8	75.5 +/- 2	N	0	0	0	0	0	
4	67.6 +/- 1.2	76.1 +/- 1.5	N	0	0	0	0	0	
5	69.6 +/- 0.9	73.8 +/- 2.4	N	0	0	0	0	0	
6	65.8 +/- 1.1	75.2 +/- 2.2	N	0	0	0	0	0	
7	69.3 +/- 0.7	76.1 +/- 1.5	N	0	0	0	0	0	
8	66.4 +/- 1	73.7 +/- 1.9	N	0	0	0	0	0	
9	69.2 +/- 1.2	76.1 +/- 2.3	N	0	0	0	0	0	
10	65.6 +/- 1.4	74.9 +/- 1.7	N	0	0	0	0	0	
Mice	Human CD45+ cells (% +/- S.D.)	Human T cells (% +/- S.D.)	HIV-1 positive mice	Week 1	Week 2	Week 3	Week 6	Week 12	% of Protection
1	66.4 +/- 1.3	73.5 +/- 2.3	N	0	0	0	0	0	1.75 µM TDF + 0.1094 µM FTC + 0.109 mg/mL VRC01
2	63.8 +/- 2.4	76.1 +/- 1.8	N	0	0	0	0	0	
3	65.1 +/- 1.8	72.6 +/- 2.5	Y	0.7 +/- 0.2	1.2 +/- 0.3	1.5 +/- 0.2	2.1 +/- 0.3	2.2 +/- 0.3	
4	65.7 +/- 1.5	74.2 +/- 1.9	N	0	0	0	0	0	
5	64.6 +/- 2.2	73.8 +/- 1.6	N	0	0	0	0	0	
6	63.8 +/- 1.9	77.2 +/- 2.1	N	0	0	0	0	0	
7	64.6 +/- 1.3	74.2 +/- 1.6	N	0	0	0	0	0	
8	66.7 +/- 1.3	76.2 +/- 2.2	N	0	0	0	0	0	
9	66.8 +/- 2.1	74.6 +/- 1.8	N	0	0	0	0	0	
10	63.7 +/- 2.2	73.7 +/- 2	N	0	0	0	0	0	
Mice	Human CD45+ cells (% +/- S.D.)	Human T cells (% +/- S.D.)	HIV-1 positive mice	Week 1	Week 2	Week 3	Week 6	Week 12	% of Protection
1	65.2 +/- 1.1	74.2 +/- 1.5	N	0	0	0	0	0	1.5 µM TDF + 0.0938 µM FTC + 0.0938 mg/mL VRC01
2	62.9 +/- 1.4	77.1 +/- 2.1	N	0	0	0	0	0	
3	63.6 +/- 1.5	73.7 +/- 2.3	Y	0.6 +/- 0.1	1.1 +/- 0.2	1.6 +/- 0.4	2.3 +/- 0.2	2.4 +/- 0.2	
4	66.1 +/- 2.1	77.1 +/- 2.4	N	0	0	0	0	0	
5	62.9 +/- 1.6	75.2 +/- 1.8	N	0	0	0	0	0	
6	64.4 +/- 2	75.3 +/- 1.6	Y	0.7 +/- 0.2	1.3 +/- 0.3	1.8 +/- 0.3	2.2 +/- 0.3	2.3 +/- 0.4	
7	65.2 +/- 1.7	75.1 +/- 2.2	N	0	0	0	0	0	
8	68.3 +/- 1.3	77.4 +/- 1.8	Y	0.9 +/- 0.3	1.4 +/- 0.2	1.8 +/- 0.4	2.4 +/- 0.4	2.2 +/- 0.3	
9	63.1 +/- 1.5	75.5 +/- 2.4	N	0	0	0	0	0	
10	65.4 +/- 1.9	73.7 +/- 1.9	N	0	0	0	0	0	
Mice	Human CD45+ cells (% +/- S.D.)	Human T cells (% +/- S.D.)	HIV-1 positive mice	Week 1	Week 2	Week 3	Week 6	Week 12	% of Protection
1	64.4 +/- 2.2	73.4 +/- 2.2	Y	0.6 +/- 0.2	1.0 +/- 0.2	1.4 +/- 0.3	2.1 +/- 0.4	2.3 +/- 0.3	1.25 µM TDF + 0.0781 µM FTC + 0.0781 mg/mL VRC01
2	62.9 +/- 1.6	71.3 +/- 1.6	N	0	0	0	0	0	
3	64.6 +/- 2.1	73.3 +/- 1.8	N	0	0	0	0	0	
4	66.2 +/- 1.5	74.2 +/- 1.3	Y	0.7 +/- 0.1	1.3 +/- 0.3	1.7 +/- 0.3	2.4 +/- 0.2	2.2 +/- 0.4	
5	65.1 +/- 1.8	71.8 +/- 1.5	Y	0.5 +/- 0.1	1.2 +/- 0.2	1.5 +/- 0.2	2.3 +/- 0.1	2.4 +/- 0.3	
6	63.3 +/- 1.5	75.7 +/- 2.1	Y	0.4 +/- 0.2	1.0 +/- 0.3	1.6 +/- 0.3	2.2 +/- 0.3	2.3 +/- 0.1	
7	66.2 +/- 2.3	77.2 +/- 1.6	N	0	0	0	0	0	
8	65.3 +/- 1.9	72.9 +/- 1.7	Y	0.6 +/- 0.1	1.2 +/- 0.3	1.7 +/- 0.4	2.2 +/- 0.4	2.6 +/- 0.2	
9	63.8 +/- 2.1	74.2 +/- 2.1	N	0	0	0	0	0	
10	64.1 +/- 1.7	73.7 +/- 1.9	Y	0.5 +/- 0.2	1.3 +/- 0.4	1.8 +/- 0.3	2.4 +/- 0.3	2.4 +/- 0.6	
Mice	Human CD45+ cells (% +/- S.D.)	Human T cells (% +/- S.D.)	HIV-1 positive mice	Week 1	Week 2	Week 3	Week 6	Week 12	% of Protection
1	63.1 +/- 0.6	72.5 +/- 2.2	Y	0.4 +/- 0.1	1.2 +/- 0.3	1.6 +/- 0.3	2.2 +/- 0.4	2.3 +/- 0.1	0.5 µM TDF + 0.0313 µM FTC + 0.0313 mg/mL VRC01
2	64.1 +/- 1.2	70.8 +/- 1.6	Y	0.5 +/- 0.2	0.9 +/- 0.1	1.4 +/- 0.2	1.8 +/- 0.3	2.2 +/- 0.3	
3	62.9 +/- 2.1	75.5 +/- 1.1	Y	0.6 +/- 0.2	1.0 +/- 0.2	1.6 +/- 0.4	2.1 +/- 0.3	2.6 +/- 0.5	
4	65.2 +/- 1.7	76.3 +/- 3.1	Y	0.6 +/- 0.1	1.3 +/- 0.2	1.5 +/- 0.3	2.3 +/- 0.4	2.4 +/- 0.4	
5	63.2 +/- 2.3	73.3 +/- 0.7	Y	0.4 +/- 0.2	0.9 +/- 0.2	1.5 +/- 0.1	2.0 +/- 0.3	2.3 +/- 0.2	
6	65.3 +/- 3.1	75.5 +/- 1.9	Y	0.5 +/- 0.1	1.1 +/- 0.3	1.5 +/- 0.2	2.2 +/- 0.4	2.6 +/- 0.4	
7	64.4 +/- 2.5	71.6 +/- 2.4	Y	0.5 +/- 0.2	1.3 +/- 0.1	1.7 +/- 0.3	2.1 +/- 0.2	2.3 +/- 0.4	
8	66.1 +/- 1.9	74.8 +/- 1.6	Y	0.6 +/- 0.2	1.2 +/- 0.1	1.7 +/- 0.4	2.5 +/- 0.4	2.4 +/- 0.2	
9	64.4 +/- 2.2	72.7 +/- 0.9	Y	0.3 +/- 0.1	0.9 +/- 0.2	1.3 +/- 0.2	1.9 +/- 0.3	2.2 +/- 0.4	
10	62.8 +/- 3.3	71.5 +/- 1.8	Y	0.4 +/- 0.2	1.0 +/- 0.2	1.7 +/- 0.2	2.4 +/- 0.5	2.4 +/- 0.2	

Plasma viral RNA (10<sup>5</sup> copies/mL)

**NOTE: VRC01-N active makes up 50% of the mass indicated above; the remainder consists of excipients**

Appendix D: Median-effect data used in the analysis.

Median-Effect Data							
VRC01-N, single drug			TDF-FTC-VRC01-N				
Log(D) (nM)	Efficacy (%)	log(D) (nM)	Efficacy (%)		Study 1	Study 2	
			Study 1	Study 2			
3.503	100	3.101	20				
3.202	100	3.402	100				
2.901	50	3.703	100				
2.600	13	4.004	100				
2.299	0	4.305	100				
		2.800				0	
		3.198				40	
		3.277				70	
		3.344				90	
		3.402				100	
Log(D) (nM)	TDF	FTC	VRC01-N	Triple			
3.000	-2.601						
3.301	-0.954						
3.602	-0.176						
4.204	1.996						
4.505	1.996						
1.398		-1.591					
1.699		-0.954					
2.301		0.000					
2.602		0.602					
2.778		1.996					
3.503			1.996				
3.202			1.996				
2.901			0.000				
2.600			-0.845				
2.299			-2.601				
3.101				-0.602			
2.800				-2.601			
3.198				-0.176			
3.277				0.368			
3.344				0.954			
3.402				1.996			
				DRI			
Fa	CI Study 1	CI Study 2	Fa	TDF	FTC	VRC01-N	
0.0025		2.84	0.0025	1.47	0.64	1.68	
0.2	1.30		0.2	3.24	1.64	2.66	
0.4		1.19	0.4	3.56	1.85	2.72	
0.7		0.96	0.7	4.45	2.41	3.10	
0.9		0.74	0.9	5.90	3.34	3.73	
0.99	0.40		0.99			5.94	
0.999	0.40		0.999			5.29	
0.9999	0.41		0.9999			4.71	